Hydralazine: Direct Arteriolar Vasodilation, HFrEF Combination and Lupus Risk

Evidence-informed pharmacology monograph updated 10 November 2026. Educational content, not a substitute for patient-specific assessment, institutional protocols or current product labeling.

Overview and chemical identity

Hydralazine is an orally and parenterally available direct arteriolar vasodilator used in selected hypertension settings and combined with isosorbide dinitrate for certain HFrEF patients. Its chemical identity is 1-hydrazinophthalazine, formula C8H8N4 (hydrochloride salt C8H8N4·HCl), not the incorrect C10H14N2O or a benzothiazine. It is not usually preferred as first-line uncomplicated chronic hypertension treatment [1,2].

Pharmacodynamic mechanism

Hydralazine relaxes vascular smooth muscle preferentially in resistance arterioles, lowering afterload and BP. Its precise intracellular molecular mechanism is not completely established; effects involving vascular calcium handling, redox signaling and endothelial pathways have been proposed. It is misleading to present a single certain eNOS–NO–cGMP pathway as established for hydralazine. Venous dilation is comparatively limited, explaining its complementary effects with predominantly venodilating nitrates [1].

Clinical applications

Hydralazine is used for hypertension when other choices are insufficient or unsuitable, and IV hydralazine may be used in selected monitored obstetric severe-hypertension protocols. The 2022 AHA/ACC/HFSA guideline recommends hydralazine plus isosorbide dinitrate for self-identified African American patients with NYHA III–IV HFrEF already receiving optimal treatment; the combination can also be considered when ARNI/ACEi/ARB cannot be used. Hydralazine alone has no equivalent established survival benefit in HFrEF [2].

Pharmacokinetics and acetylator status

Hydralazine undergoes extensive first-pass metabolism, including N-acetylation; genetically influenced acetylator status contributes to variable exposure and lupus susceptibility. Oral effects and dosing frequency differ from parenteral protocols, which need individualized assessment. Renal or hepatic impairment and interacting therapies may require extra monitoring [1].

Adverse reactions and monitoring

Reflex tachycardia, palpitations, headache, flushing and fluid/sodium retention are common. In patients with coronary disease, tachycardia can aggravate angina. A lupus-like autoimmune syndrome can develop, particularly with greater cumulative exposure, higher doses and slow-acetylator status; symptoms may include arthralgia, fever and serositis. Rare ANCA-associated vasculitis, kidney injury or blood-count abnormalities can occur. Review symptoms, blood pressure and relevant laboratory tests when clinically indicated [1].

Interactions and precautions

Other antihypertensives can produce additive hypotension, while some treatment regimens use a beta blocker and diuretic to counter reflex tachycardia and fluid retention. Avoid unmonitored rapid BP lowering. Clinical decisions in pregnancy, coronary artery disease or heart failure depend on setting, accompanying drugs and monitoring rather than indiscriminate hydralazine escalation [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. DailyMed. Hydralazine hydrochloride tablets: US prescribing information, updated February 2, 2026. Available from: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3d1786d-c3ff-42f1-a09f-37a9c9021e5a
  3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145:e895–e1032. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2021.12.012
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *